Peroral antidiabetics and thyroid diseases

Czech version

Authors: Štefan Sotak
Authors‘ workplace: I. interná klinika LF UPJŠ a UNLP Košice
Published in: Diab Obez 2020; 20(39): 42-46
Category:

Overview

Thyroid diseases and type 2 diabetes mellitus are the two most common endocrinological diseases worldwide. The relationship between type 1 diabetes mellitus and thyroid diseases is known and described, but the relationship between thyreopathies and type 2 diabetes is not clarified sufficiently through that studies manifest increasingly the connection between them. Diabetes also can affect thyroid gland function indirectly by some peroral antidiabetics.

Keywords:

metformin – type 2 diabetes mellitus – peroral antidiabetics – thyroid diseases

Sources

Buse JB, Polonsky KS, Burant CF. Type 2 Diabetes Mellitus. In: Melmed S, Polonsky KS, Larsen PR et al. Williams Textbook of Endocrinology. Elsevier: Philadelphia 2010: 1329–1358. ISBN 978–14–3770–324–5.
Vondra K, Vrbíková J, Zamrazil V. Diabetes mellitus a onemocnení štítné žlázy. In: Stárka L et al. Pokroky v endokrinologii. Maxdorf: Praha 2007: 656–668. ISBN 978–80–7345–129–5.
Pelikánová T. Endokrinný pankreas a diabetes mellitus. In: Kreze A, Langer P, Klimeš I et al. Všeobecná a klinická endokrinológia. Academic Electronic Press: Bratislava 2004: 567–750. ISBN 80–88880–58–0.
Hage M, Zantout MS, Azar ST. Thyroid Disorders and Diabetes Mellitus. J Thyroid Res 2011; 2011: 439463. Dostupné z DOI: <http://dx.doi.org/10.4061/2011/439463>.
Chen TM, Lin CC, Huang PT et al. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2011; 26(5): 858–865. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1440–1746.2011.06664.x>.
Díez JJ, Sánchez P, Iglesias P. Prevalence of thyroid dysfunction in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2011; 119(4): 201–207. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0031–1271691>.
Al-Attas OS, Al-Daghri NM, Alkharfy KM et al. Urinary iodine is associated with insulin resistance in subjects with diabetes mellitus type 2. Exp Clin Endocrinol Diabetes 2012; 120(10): 618–622. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0032–1323816>.
Díez JJ, Iglesias P. Subclinical hyperthyroidism in patients with type 2 diabetes. Endocrine 2012; 42(1): 157–163. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0031–1271691>.
Kouidhi S, Berhouma R, Ammar M et al. Relationship of thyroid function with obesity and type 2 diabetes in euthyroid Tunisian subjects. Endocr Res 2013; 38(1): 15–23. Dostupné z DOI: <http://dx.doi.org/10.3109/07435800.2012.699987>.
Sousa Vergara Palma CC, Pavesi M, Guedes Nogueira V et al. Prevalence of thyroid dysfunction in patients with diabetes mellitus. Diabetol Metab Syndr 2013; 5: 58. Dostupné z DOI: <http://dx.doi.org/10.1186/1758–5996–5-58>.
Balkan F, Onal ED, Usluogullari A et al. Is there any association between insulin resistance and thyroid cancer? A case control study. Endocrine 2014; 45(1): 55–60. Dostupné z DOI: <http://dx.doi.org/10.1007/s12020–013–9942-x>.
Sotak Š, Lazúrová I, Felšőci M. Výskyt diabetes mellitus 2. typu u pacientov s autoimunitnou tyroiditídou v štádiu hypotyreózy. Vnit Lek 2018; 64(3): 232–235.
Lim CT, Kola B, Corbonits M. AMPK as a mediator of hormonal signalling. J Mol Endocrinol 2010; 44(2): 87–97. Dostupné z DOI: <http://dx.doi.org/10.1677/JME-09–0063>.
Łabuzek K, Suchy D, Gabryel B et al. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010; 62(5): 956–965. Dostupné z DOI: <http://dx.doi.org/10.1016/s1734–1140(10)70357–1>.
Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab 2006; 91(1): 225–227. <http://dx.doi.org/10.1210/jc.2005–1210>.
Cappelli C, Rotondi M, Pirola I et al. TSH-lowering effect of metformin in type 2 diabetic patients. Differences between euthyroid, untreated hypothyroid and euthyroid on L-T4 therapy patients. Diabetes Care 2009; 32(9): 1589–1590. Dostupné z DOI: <http://dx.doi.org/10.2337/dc09–0273>.
Cappelli C, Rotondi M, Pirola I. Thyreotropin levels in diabetic patients on metformin treatment. Eur J Endocrinol 2012; 167(2): 261–265. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-12–0225>.
Krysiak R, Gilowska M, Szkróbka W et al. The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and amiodarone-induced hypothyroidism. Pharmacol Rep 2016; 68(2): 490–494. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pharep.2015.11.010>.
Isidro ML, Penín MA, Nemiña R et al. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 2007; 32(1): 79–82. Dostupné z DOI: <http://dx.doi.org/10.1007/s12020–007–9012–3>.
Distiller LA, Polakow ES, Joffe BI. Type 2 diabetes mellitus and hypothyroidism: the possible influence of metformin therapy. Diabet Med 2014; 31(2): 172–175. Dostupné z DOI: <http://dx.doi.org/10.1111/dme.12342>.
Fournier JP, Yin H, Yu OH et al. Metformin and low levels of thyroid-stimulating hormone in patients with type 2 diabetes mellitus. CMAJ 2014; 186(15): 1138–1145. Dostupné z DOI: <http://dx.doi.org/10.1503/cmaj.140688>.
Cappelli C, Rotondi M, Pirola I et al. Metformin-induced thyrotropin suppression is not associated with cardiac effects. Hormones (Athens) 2014; 13(2): 252–258. Dostupné z DOI: <http://dx.doi.org/10.1007/BF03401339>.
Krysiak R, Okopień B. The effect of metformin on the hypothalamic–pituitary–thyroid axis in women with polycystic ovary syndrome and subclinical hypothyroidism. J Clin Pharmacol 2015; 55(1): 45–49. Dostupné z DOI: <http://dx.doi.org/10.1002/jcph.373>.
Krysiak R, Skróbka W, Okopień B. The effect of metformin on the hypothalamic-pituitary-thyroid axis in patients with type 2 diabetes and subclinical hyperthyroidism. Exp Clin Endocrinol Diabetes 2015; 123(4): 205–208. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0034–1398621>.
Krysiak R, Skróbka W, Okopień B. The effect of metformin on hypothalamic-pituitary-thyroid axis activity in women with interferon-induced hypothyroidism: A pilot study. Exp Clin Endocrinol Diabetes 2016; 124(2): 71–76. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0035–1565207>.
Krysiak R, Skróbka W, Okopień B. Sex-dependent effect of metformin on hypothalamic-pituitary-thyroid axis activity in patients with subclinical hypothyroidism. Pharmacol Rep 2016; 68(6): 1115–1119. Dostupné z DOI: <http://dx.doi.org/10.1016/j.pharep.2016.07.002>.
Santos-Palacios S, Brugos-Larumbe A, Guillen-Grima F et al. Does metformin have a “buffer effect” on serum TSH levels in euthyroid diabetic patients? Hormones (Athens) 2015; 14(2): 280–285. Dostupné z DOI: <http://dx.doi.org/10.14310/horm.2002.1559>.
Díez JJ, Iglesias P. 2013 Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clin Endocrinol 2013; 78(4): 505–511. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2012.04468.x>.
Morteza Taghavi S, Rokni H, Fatemi S. Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diab Vasc Dis Res 2011; 8(1): 47–48. Dostupné z DOI: <http://dx.doi.org/10.1177/1479164110391917>.
Rotondi M, Cappelli M, Magri F et al. Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2011; 75(3): 378–381. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2011.04042.x>.
López M, Varela L, Vázquez MJ et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010; 16(9): 1001–1008. Dostupné z DOI: <http://dx.doi.org/10.1038/nm.2207>.
Duntas LH, Orgiazzi J, Brabant G. The interface between thyroid and diabetes mellitus. Clin Endocrinol (Oxf) 2011; 75(1): 1–9. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2265.2011.04029.x>.
Rezzónico J, Rezzónico M, Pusiol E et al. Metformin treatment for small benign thyroid nodules in patients with insulin resistance. Metab Syndr Relat Disord 2010; 9(1): 69–75. Dostupné z DOI: <http://dx.doi.org/10.1089/met.2010.0026>.
Ittermann T, Markus MRP, Schipf S et al. Metformin inhibits goitrogenous effect of type 2 diabetes. Eur J Endocrinol 2013; 169(1): 9–15. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-13–0101>.
Schipf S, Schmidt CO, Alte D et al. Smoking prevalence in type 2 diabetes: results of the Study of Health in Pomerania and The German National Health Interview and Examination Survey. Diabet Med 2009; 26(8): 791–797. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1464–5491.2009.02784.x>.
Völzke H, Schwahn C, Kohlmann T et al. Risk factors for goiter in a previously iodine-deficient region. Exp Clin Endocrinol Diabet 2005; 113(9): 507–515. Dostupné z DOI: <http://dx.doi.org/10.1055/s-2005–865741>.
Giovannucci E, Harlan DM, Archer MC et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33(7): 1674–1685. Dostupné z DOI: <http://dx.doi.org/10.2337/dc10–0666>.
Tseng CH. Rosiglitazone may reduce thyroid cancer risk in patients with type 2 diabetes. Ann Med 2013; 45(8): 539–544. Dostupné z DOI: <http://dx.doi.org/10.3109/07853890.2013.851865>.
Chen TM, Lin CC, Huang PT et al. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2013; 26(5): 858–865. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1440–1746.2011.06664.x>.
Nikkilä EA, Jakobson T, Jokipii SJ et al. Thyroid function in diabetic patients under long-term sulfonylurea treatment. Acta Endocrinol (Copenh) 1960; 33: 623–629. Dostupné z DOI: <http://dx.doi.org/10.1530/acta.0.XXXIII0623>.
Sugrue DD, McEvoy M, Drury MI. Thyroid disease in diabetics. Postgrad Med J 1982; 58(685): 680–684. Dostupné z DOI: <http://dx.doi.org/10.1136/pgmj.58.685.680>.
Kim HK, Yoon JH, Kim SJ et al. Higher TSH level is a risk factor for differentiated thyroid cancer. Clin Endocrinol (Oxf) 2013; 78(3): 472–477. Dostupné z DOI: <http://dx.doi.org/10.1111/cen.12027>.
Güney E, Efe B, Akalin A et al. Thyroid Disease in Diabetes Mellitus. Turk J Endocrinol Metab 1999; 3(3): 119–122.
Merkhan MM. The effects of glibenclamide on thyroid function tests in type 2 diabetic patients. Iraq J Pharm 2013; 13(2): 56–61. Dostupné z DOI: <http://dx.doi.org/10.33899/iphr.2013.86556>.
Hu N, Gutsmann A, Herbert DC et al. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene 1994; 9(4): 1021–1027.
Schultes B, Oltmanns KM, Kern W et al. Acute and prolonged effects of insulin-induced hypoglycemia on the pituitary-thyroid axis in humans. Metabolism 2002; 51(10): 1370–1374. Dostupné z DOI: <http://dx.doi.org/10.1053/meta.2002.35193>.
Menaka R, Sehgal M, Lakshmi M et al. Thiazolidinedione precipitated thyroid associated ophthalmopathy. J Assoc Physicians India 2010; 58: 255–257.
Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 2014; 11(3–4): 202–230. Dostupné z DOI: <http://dx.doi.org/10.1900/RDS.2014.11.202>.
Wang C. The relationship between type 2 diabetes mellitus and related thyroid diseases. J Diabetes Res 2013; 390534. Dostupné z DOI: <http://dx.doi.org/10.1155/2013/390534>.
Karimifar M, Aminorroaya A, Amini M et al. Effect of metformin on thyroid stimulating hormone and thyroid volume in patients with prediabetes: A randomized placebo-controlled clinical trial. J Res Med Sci 2014; 19(11): 1019–1026.